RBC Capital assumed LDR share coverage in June.
Here are five things to know about the company’s stock:
• Price target: $34
• Potential upside: 9.25 percent from the stock’s previous close
• LDR traded up 1.08 percent mid-day Monday
• Market cap: $313.2 million
• Average volume: 55,9985
Piper Jaffray separately raised LDR’s price target from $38 to $40 in early August, and they now have an “overweight” rating on the stock. An additional five equities research analysis gave LDR a “Buy” rating with $35.50 as the price target, according to the report.
The company reported total revenue was up 30.7 percent for the second quarter of 2014 to $34.8 million. Exclusive technology products grew 40.9 percent to $30 million in the quarter. Overall revenue in the United States was up 40 percent to $26.3 million.
LDR increased revenue guidance for the full year 20 percent to 21 percent, which would put the company at around $134 million to $135 million for the year. This would be a 15 percent to 16 percent growth over 2013.
More articles on orthopedic devices:
Spine Wave launches access product portfolio
Amedica, Spinal Kinetics partner
20 spine devices receive FDA 510(k) clearance in September
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
